Compare BioNTech SE - ADR (BNTX) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Salesforce Inc — how do they compare? BioNTech SE - ADR trades at $93.32 (market cap $23.31B), while Salesforce Inc trades at $192.11 (market cap $161.73B). The key difference: Salesforce Inc is far larger — about 6.9× BioNTech SE - ADR's market cap, and Salesforce Inc pays a 0.89% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | CRM | |
|---|---|---|
Market Cap | $23.31B | $161.73B |
Sector | Health | Technology |
52-Week High | $119.34 | $266.23 |
52-Week Low | $83.89 | $150.12 |
Enterprise Value | $6.60B | $191.77B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Salesforce (CRM) trades at $192.28, down 2.65% today amid a broader tech sell-off, but maintains strong fundamentals with consistent earnings beats, robust profitability margins, and solid cash flow growth. The stock exhibits a bullish technical trend with key support at $193, while analyst consensus remains overwhelmingly positive with a $230.83 price target. Recent news highlights AI-driven growth potential but also sector-wide volatility concerns.
Outlook is favorable given CRM's rule of 44 performance, AI monetization momentum, and discounted valuation, though risks include competitive pressures, macroeconomic headwinds, and elevated RSI levels suggesting near-term overbought conditions. The company's double-digit revenue growth and expanding margins support long-term upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
